


Modified PvDBP-RII subdomain 3 for a polypeptide vaccine for Plasmodium vivax

Modified PvDBP-RII subdomain 3 for a polypeptide vaccine for *Plasmodium vivax*.

Applications: Synthetic polypeptide, vaccination against Plasmodium vivax

PvDBP-RII is the leading vaccine candidate for malaria caused by *Plasmodium vivax*. We have used rational methods to design a new vaccine immunogen (interface) which is better than PvDBP-RII in pre-clinical studies.



Features	Benefits
Novel immunogen based on modified Duffy binding domain (DBP) of Plasmodium vivax, specifically subdomain 3 of the PvDBP-RII protein domain	Effectively target the reticulocyte invasion stage of Plasmodium vivax to prevent symptoms and malaria transmission
Structure-guided immunogen design, which modifications allows production of correctly folded form	Modifications leading to immunogen allows effective production and scalability, hence effective vaccination
Preclinical data demonstrates a more effective growth-inhibitory antibody repertoire compared to the current best PvDBP-RII immunogen	Ready to be tested in clinical trials
Immunogen can be included in prophylaxis for Malaria by itself or in combination with other components as a multi-stage vaccine	Can be used for analysing antibody repertoire generated in response to vaccination or natural infection

Features

Benefits

Adaptability in vaccine program design

Awaiting patent and Available for

- Co-development
 - Licensing
-

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided 'as is' without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.